Get the Stockscreener App
0.81
9.29%
-0.083
Pre-market:
.83
0.02
+2.47%
Fibrobiologics Inc stock is traded at $0.81, with a volume of 135.30K.
It is down -9.29% in the last 24 hours and down -22.86% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$0.893
Open:
$0.8662
24h Volume:
135.30K
Relative Volume:
0.33
Market Cap:
$4.22M
Revenue:
-
Net Income/Loss:
$-18.68M
P/E Ratio:
-0.1095
EPS:
-7.3948
Net Cash Flow:
$-15.70M
1W Performance:
-12.90%
1M Performance:
-22.86%
6M Performance:
-83.18%
1Y Performance:
-94.92%
1-Day Range:
$0.7849
$0.875
1-Week Range:
$0.7849
$1.04
52-Week Range:
$0.7849
$16.20
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.81 | 4.65M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FBLG Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances PipelineHigh Estimate Range - newsline.com
FibroBiologics (FBLG) Declines Amid Volatility, Nears Critical Support ZoneValue Area Low - newsline.com
FibroBiologics Inc. (FBLG) Slides 3% as Selling Pressure Tests Key Support ZoneEnding Diagonal - newsline.com
FIBROBIOLOGICS INC (FBLG) Stock Chart - ChartMill
FibroBiologics Inc. (FBLG) Q1 2026 Earnings: Narrow EPS Miss Highlights Pre-Revenue Biotech Challenges - newsline.com
FBLG: Phase 1/2 Trial of CYWC628 Underway - Zacks Small Cap Research
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - Sahm
FibroBiologics begins dosing patients in diabetic ulcer trial By Investing.com - Investing.com South Africa
FibroBiologics begins dosing patients in diabetic ulcer trial - Investing.com UK
FibroBiologics (FBLG) Begins Clinical Trial for Diabetic Foot Ulcers Treatment - GuruFocus
Fibrobiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial Evaluating Cywc628 For The Treatment Of Diabetic Foot Ulcers - TradingView
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers - The Manila Times
Experimental cell therapy for diabetic foot ulcers starts dosing patients - Stock Titan
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data? - Insider Monkey
10 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
FBLG Stock Price, Quote & Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - Sahm
D. Boral Capital Maintains FibroBiologics (FBLG) Buy Recommendation - MSN
symbol__ Stock Quote Price and Forecast - CNN
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics files patent for oral fibroblast delivery system - Investing.com UK
FibroBiologics files patent for oral fibroblast delivery system By Investing.com - Investing.com Australia
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics - GlobeNewswire
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
TradingKey - TradingKey
Fibrobiologics explores use of fibroblast platform for hantavirus - BioWorld News
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewswire
Severe Hantavirus syndrome lacks drugs, FibroBiologics tests fibroblast therapy - Stock Titan
FibroBiologics, Inc. Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
FibroBiologics | 424B5: Prospectus - Moomoo
FBLG | FibroBiologics, Inc. Common Stock Executive Compensation - Quiver Quantitative
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics Grants Stock Options to Key Executives - The Globe and Mail
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrobiologics Inc Stock (FBLG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):